• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.

    6/24/24 10:01:21 AM ET
    $TARO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TARO alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-35463
    Issuer: TARO PHARMACEUTICAL INDUSTRIES LTD
    Exchange: NEW YORK STOCK EXCHANGE LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 14 HAKITOR STHAIFA BAY
    Haifa 26110
    Telephone number: +972 9 971 1800
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Ordinary Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-06-24 By Nicolas Connolly Analyst, Regulation
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TARO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARO

    DatePrice TargetRatingAnalyst
    1/18/2024$43.00Buy → Neutral
    H.C. Wainwright
    1/31/2022$75.00 → $73.00Buy
    HC Wainwright & Co.
    1/18/2022$82.00 → $75.00Buy
    HC Wainwright & Co.
    7/28/2021$80.00 → $82.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TARO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sun Pharma Completes Taro Merger

      Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J., June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") with its subsidiary.  As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-own

      6/24/24 7:47:00 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Shareholders Approve Merger with Sun Pharma

      MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.

      5/23/24 7:50:00 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Provides Results for Year Ended March 31, 2024

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $87.4 million (53.0% of net sales) compared to $75.7 million (51.6% of net sales). Research and development (R&D) expenses of $20.5 million increased $4.2 million. Selling, marketing, general and administrative expenses (SG&A

      5/20/24 5:00:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Leadership Updates

    Live Leadership Updates

    See more
    • Taro Appoints New Chief Financial Officer

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today. Mr. Coote has over 25 years of significant financial executive experience; most recently serving as Taro's AVP, Treasurer and Business Finance since 2008. Prior to joining Taro, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young. Throughout his career, he has been accountable for areas such as: Accounting, Treasury, Budgeting, Financial Planning and Analysis, Acquisitions, Investor R

      12/1/21 5:05:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro Announces Resignation of Chief Financial Officer

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities. Mr. Uday Baldota, Taro's CEO, stated, "On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors." The Company has initiated a search for a successor as Chief Financial Officer. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, de

      7/14/21 5:54:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Taro Pharm downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Taro Pharm from Buy to Neutral and set a new price target of $43.00

      1/18/24 7:15:24 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

      HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $73.00 from $75.00 previously

      1/31/22 6:44:12 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Taro Pharmaceutical Indus with a new price target

      HC Wainwright & Co. reiterated coverage of Taro Pharmaceutical Indus with a rating of Buy and set a new price target of $75.00 from $82.00 previously

      1/18/22 9:38:57 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TARO
    SEC Filings

    See more

    $TARO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TARO
    Financials

    Live finance-specific insights

    See more
    • SEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.

      15F-12B - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)

      7/5/24 11:25:50 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.

      25-NSE - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 10:01:21 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.

      SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 7:09:07 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      6/24/24 7:27:26 AM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      1/17/24 4:35:31 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

      SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)

      12/11/23 4:30:41 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro to Release Third Quarter Results on January 25, 2024

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswir

      1/19/24 4:15:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro to Release Second Quarter Results on October 26, 2023

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businessw

      10/19/23 4:30:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Taro to Release First Quarter Results on July 26, 2023

      Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: h

      7/19/23 4:00:00 PM ET
      $TARO
      Biotechnology: Pharmaceutical Preparations
      Health Care